{"task_id": "ffde47f25caf6b01", "source": "Approach to Internal Medicine_ A Resource Book for Clinical Practice ( PDFDrive ).pdf (Part 202/464)", "text": "positive (see\nbelow for details)\nBreast Cancer\n191\n\n--- Page 213 ---\nMANAGEMENT (CONT\u2019D)\nSTAGE IV\n1. HORMONAL\nif ER/PR positive, non visceral disease\n(i.e. bony, sometimes lung), non bulky and not\nhighly symptomatic, consider aromatase inhibi\ntors, tamoxifen, or fulvestrant. Oophorectomy or\nLHRH agonists for premenopausal women\n2. PALLIATIVE CHEMOTHERAPY\nfor visceral or ER/PR\nnegative disease. Choices include anthracyclines,\ntaxanes,\ngemcitabine,\ncapecitabine,\nand\nvinorelbine\n3. BIOLOGICAL THERAPY\nfor Her2+ disease, add tras\ntuzumab to chemotherapy and continue mainte\nnance trastuzumab until disease progression. The\nrole of newer targeted therapies including lapati\nnib (dual tyrosine kinase inhibitor of EGFR and\nHER2) and bevacizumab (anti VEGF) is expanding\nin pre treated patients\n4. PALLIATIVE RADIATION\nfor symptom control\n5. BISPHOSPHONATES\nif bone metastasis, pamidro\nnate 90 mg IV over 1 2h q1month, or zoledronate\n4 mg IV\nLOCAL RECURRENCE\nbiopsy to try to distinguish\nrecurrence from new primary, metastatic workup. If\nisolated local recurrence, resection/completion mas\ntectomy \u0006 radiation. Hormonal and/or chemother\napy may also be considered\nRelated Topics\nBRCA Mutations (p. 224)\nCancer Screening (p. 222)\nBREAST SURGERY OVERVIEW\nCOMPLETE SURGERY\nmodified radical mastect\nomy, radical mastectomy. Indications for mastectomy\ninclude multicentric disease, diffuse malignant\nappearing microcalcifications on mammography,\nprior breast radiation, and pregnancy. Relative indi\ncations include large tumor (>5 cm), connective\ntissue\ndisease\n(radiation\ncontraindicated),\nand\npatient preference. Poorer cosmesis compared to\nbreast conserving surgery\nBREAST\nCONSERVING\nSURGERY\nexcisional\nbiopsy, lumpectomy, partial mastectomy, quadran\ntectomy, wide local excision\nSURGICAL MARGIN\npositive margin is defined as\ntumor touching ink and would require either re exci\nsion (preferred) or radiation (boost). Close margin is\ndefined as tumor <2 mm from ink mark\nAXILLARY LYMPH NODE DISSECTION (ALND)\nused\nin all invasive carcinoma or in situ disease >5 cm. May\nbe avoided if sentinel lymph node negative\nBREAST SURGERY OVERVIEW (CONT\u2019D)\nSENTINEL LYMPH NODE BIOPSY\nindicated for\nsize <3 cm and clinically N0 tumors. Contraindica\ntions include locally advanced breast cancer, multi\nfocal cancers, previous disruptive breast procedures,\npalpable axillary nodes, and adverse reactions to\ndyes. Proceed to ALND if positive nodes, unable to\nidentify sentinel node, or any two of the following\nfeatures (grade 3, lymphovascular invasion, T2 tumor)\nHORMONAL THERAPY OVERVIEW\nHORMONAL REGIMENS\n\u0002\nOVARIAN ABLATION (premenopausal only)\noophor\nectomy, radiation, LHRH agonists (goserelin 3.6 mg\nIM every month, leuprolide). Combined with\ntamoxifen (in adjuvant or metastatic settings) or\naromatase inhibitors (in metastatic setting only)\nfor maximal effect\n\u0002\nSELECTIVE ESTROGEN RECEPTOR MODULATORS (preme\nnopausal or postmenopausal)\ntamoxifen 20 mg\nPO daily. Side effects include hot flashes, mood\nswings, vaginal discharge, thromboembolism, and\nendometrial cancer. Protective effect with bones\nand lipids\n\u0002\nAROMATASE\nINHIBITORS\n(for\npostmenopausal\nwomen or premenopausal women after ovarian\nablation as suppress peripheral estrone production\nonly)\ninhibit aromatase, an enzyme in skin, adi\npose tissue, and breast that converts androstene\ndione (from the adrenals) to estrone and estradiol.\nSteroidal (exemestane 25 mg PO daily), non ster\noidal (letrozole 2.5 mg PO daily, anastrozole 1 mg\nPO daily). Side effects include hot flashes, mood\nswings, vaginal dryness, myalgia/arthralgia, head\nache, osteoporosis, dyslipidemia, weight gain, and\npotentially CAD\n\u0002\nANTIESTROGEN\nfulvestrant 250 500 mg IM monthly\nis equivalent to aromatase inhibitors in first line\nmetastatic setting\n\u0002\nOTHERS\nmegestrol acetate 160 mg PO daily,\nmethyltestosterone\nPREDICTIVE FACTORS FOR HORMONAL THER\nAPY\ndegree of response to tamoxifen varies\n(ER+PR+ >ER+PR >ER PR+ >ER PR ). Hormonal\ntherapy not given to patients with ER\nand PR\ncancers. Her2+ may also interfere with ER pathways\nAPPROACH IN THE ADJUVANT SETTING\nfor pre\nmenopausal women, consider tamoxifen \u00035 years.\nFor postmenopausal women, consider tamoxifen\n\u00032 3 years, followed by exemestane or anastrozole\nto complete 5 years of adjuvant hormonal therapy,\nletrozole \u00035 years, anastrozole \u00035 years, or tamox\nifen \u00035 years followed by letrozole \u00035 years. Con\nsider aromatase inhibitors as first hormonal agent if\n>10% risk of relapse in first 2 years (e.g. \u00054 positive\n192\nBreast Cancer", "text_length": 4513, "metadata": {"source": "Approach to Internal Medicine_ A Resource Book for Clinical Practice ( PDFDrive ).pdf (Part 202/464)", "type": "chunk", "chunk_index": 201, "total_chunks": 464, "uploaded_by": "admin@admin.com", "upload_date": "2025-12-11T18:40:09.523651", "document_uuid": "fda2cab4-cdd9-4015-af24-46fd62c86d94", "filename": "Approach to Internal Medicine_ A Resource Book for Clinical Practice ( PDFDrive ).pdf", "category": "medical_pdf", "section": "body", "year": null, "outdated": false, "document_id": "fda2cab4-cdd9-4015-af24-46fd62c86d94"}, "created_at": "2025-12-11T18:40:09.524566", "status": "complete", "chunks_added": 3}